Age-related macular degeneration (AMD) is an ophthalmologically intractable fundus disease and is the leading cause of low vision and blindness in people over the age of 50. In China, with the aging of the population, the incidence of age-related macular degeneration is also increasing year by year. According to statistics, the prevalence rate in people over 75 years of age in China has reached as high as 15.15%. Currently, more than 1.75 million people in the United States suffer from this disease, and it is expected to reach 3 million in 10 years. Facing the high rate of age-related macular degeneration (hereinafter referred to as AMD), the cause of the disease is not clear, and there is almost no special treatment means, many ophthalmologists at home and abroad are actively exploring the cause, pathogenesis and treatment methods of AMD. Clinically, AMD is classified into atrophic (also known as dry or non-exudative) and exudative (also known as “wet” or “discoid”) according to the morphology of the fundus. The atrophic type is mainly caused by choroidal capillary atrophy, vitreous membrane thickening and retinal pigment epithelial atrophy, which leads to atrophic degeneration of the macula. The exudative type mainly consists of choroidal neovascularization (hereafter referred to as CNV) caused by the destruction of the vitreous membrane and the invasion of choroidal vessels into the subretina, resulting in subretinal pigment epithelium or/and subneuroepithelial plasma or hemorrhagic disc detachment in the macula, which eventually becomes a mechanized scar. It has been observed that the atrophic type may also change to the exudative type, eventually leading to loss of central vision. In particular, the location of CNV is mostly close to the macula or even in the central macular recess, resulting in significant loss of central vision, so treatment of CNV is still very difficult. According to the data, exudative patients account for 10%-20% of the total number of AMD, while 80%-90% of the patients are accompanied by severe visual impairment. The causes and pathogenesis of AMD are still unclear and correlate with many factors, including genetics, chronic photodamage, malnutrition, toxicity, and immune abnormalities. It is currently believed that: retinal pigment epithelium (RPE)-choroidal hypoxia is closely related to the formation of choroidal neovascularization. Abnormal choroidal blood flow can cause RPE-choroidal hypoxia. Early studies have demonstrated decreased choroidal blood flow and inadequate perfusion in eyes with AMD, more significantly in eyes with exudative AMD. The choroid is the blood bank of the eye, and the blood supply to the central macular recess comes from the capillaries of the choroid. With aging, the compliance of the choroidal vessels decreases, the resistance to intravascular blood flow increases, and the perfusion of blood in the choroid decreases accordingly, which impairs the metabolism of the retinal pigment epithelium and leads to degeneration and atrophy of the pigment epithelium. Increased choroidal capillary pressure will also lead to a decrease in metabolic waste transported by the retinal pigment epithelium and deposited in the vitreous warts and basal lamina; the increased pressure can also cause retinal pigment epithelial detachment and choroidal neovascular membrane formation. What factors ultimately lead to the development of AMD still needs to be further explored. In recent years, photodynamic therapy has brought some hope for the treatment of this disease, followed by a new era of anti-angiogenic therapy. These two therapies are currently the mainstay of Western medical treatment for this disease, however, there are still many shortcomings in these two therapies. The former is expensive, prone to recurrence, and it is difficult to determine whether vision can be improved. For many patients with low vision, such an expensive cost is unaffordable. Currently, anti-vascular endothelial growth factor (anti-VEGF) agents, including ranibizumab (Lucentis), bevacizumab (Avastin) and pegaptanib (Macugen) have been used to treat neovascular AMD, i.e., wet AMD. these drugs are effective for CNV, but they are difficult to control CNV In particular, these drugs have not yet been approved by the domestic health authorities, so domestic patients are still in the “hope and thirst” stage. In Chinese medicine, AMD is considered to be in the category of “faint vision”. The clinical characteristics of AMD in Chinese medicine are related to the deficiency of essence, qi and blood, mainly involving kidney, spleen and liver. The clinical features of AMD in Chinese medicine are related to the deficiency of essence, qi and blood; mainly involving the kidney, spleen and liver; the types of symptoms are mostly “phlegm stasis”, “blood stagnation” and “qi deficiency”. Exudative AMD is caused by structural abnormalities of the neovascular membrane, resulting in recurrent bleeding in the macula. In “Jisheng Fang on Blood Loss”, it is believed that the pathogenesis of blood loss is due to heat more often. The “Jing Yue Quan Shu on Blood Evidence” summarizes the pathogenesis of hemorrhage as “fire” and “qi injury”. The “Theory of Blood Evidence” proposes the treatment methods of stopping bleeding, eliminating blood stasis, nourishing blood and replenishing blood. The macular edema is mostly caused by water-dampness retention and stagnation. The “Treatise on the Origin of Diseases” says: “The meridians and channels are blocked, and water is stagnant”, and then it develops into swelling. The Treatise on Blood Evidence says, “Stasis of blood and water also lead to swelling.” According to Chinese medicine, it is the pathological product of water, dampness and phlegm due to the obstruction of water transportation and excretion process, which belongs to the category of phlegm drink. Its accumulation in the macula, mostly tangible, is treated according to phlegm-drink. The accumulation of phlegm and dampness causes detachment of retinal pigment epithelium and epithelium, which in turn leads to retinal ischemia and hypoxia to produce subretinal neovascularization. Macular degeneration is mostly associated with aging, for atrophic AMD, ancestral medicine has long recognized the close relationship between aging and “liver and kidney”. The “standard rules of evidence and treatment” that “vision is dim is the disease of liver and kidney deficiency, due to Yin deficiency and blood, essence depletion”, for the liver and kidney theory of AMD treatment provides a certain basis. “Liver is the sea of blood” and “essence and blood produce each other” reveal the mechanism of regulating the rheological properties of blood by nourishing the liver and kidney. It has been reported that long-term use of Qiju Dihuang Oral Liquid or Mingmu Dihuang Pill to nourish the liver and kidneys resulted in changes in blood rheological parameters before and after treatment, which provides a basis for the treatment of AMD in Chinese medicine by nourishing the liver and kidneys. The kidney is the origin of the first day, and the spleen is the origin of the second day. The lack of essence in the elderly is closely related to the kidney and spleen. Some people take tonifying the kidneys to benefit the essence and brighten the eyes as the main treatment, in which Cistanches and Boneset tonic the Yang, dry lotus herb and lady’s mantle tonic the Yin, Astragalus tonic the Qi and ascend the Yang, Atractylodes can dry the dampness and strengthen the spleen, Dan Shen and Angelica have the function of activating the blood. For dryness, add Radix et Rhizoma Puerariae and Radix Codonopsis to strengthen the spleen. This formula has been proved by animal experiments: it can enhance the anti-tissue oxidase activity of eye tissue, scavenge free radicals, reduce peroxisome content, delay the aging of body tissue cells, and improve microcirculation. Chinese medicine has certain advantages in the treatment of AMD. From ancient times to the present, Chinese medicine has been treating this kind of disease according to evidence-based treatment. However, the shortcoming is that the standard of efficacy is only to improve visual acuity, and there is a lack of precise instruments to observe choroidal CNV lesions, so there is a lack of sufficient understanding of the occurrence and development of AMD. In the past 10 years or so, indocyanine green angiography (ICGA) and optical coherence tomography (OCT) have been introduced successively, enabling ophthalmologists to unveil the formation of CNV in AMD. There are many ways to treat this disease in TCM, such as tonics, prescription drugs, acupuncture and moxibustion therapy, but the theoretical source of the treatment is only from the theory of deficiency, from the theory of reality, and from both reality and deficiency. From ancient times to the present, there are various methods of treatment for AMD in Chinese medicine, and there is no restriction, but the main idea is based on evidence-based treatment. If the evidence is properly identified, there is indeed therapeutic effect. However, this way of thinking is not suitable for large sample observation, nor does it have the conditions to be applied. It is necessary to summarize a set of TCM prescriptions that are both guided by TCM theory and have TCM ophthalmology characteristics, which are both effective and can be promoted, in order to improve the efficiency of doctors in treating AMD.